Drugs / Moderna mRNA-1273
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05000216 | Aug 2021 → Jun 2023 | juvenile dermatomyositis, juvenile idiopathic arthritis, pediatric multiple sclerosis, pediatric systemic lupus erythematosus +3 | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moderna mRNA-1273 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05000216 ↗ |
| Modality | Vaccine | “additional dose of the Moderna COVID-19 vaccine” NCT05000216 ↗ |
| Route | Intramuscular | “One dose administered intramuscularly.” NCT05000216 ↗ |